Breaking Finance News

Vectura Group PLC (LON:VEC) stock price target held steady at 225.00GBX, issued a research note today by finnCap

Just yesterday Vectura Group PLC (LON:VEC) traded -1.61% lower at 146.20GBX. Vectura Group PLC’s 50-day moving average is 138.77GBX and its 200-day moving average is 147.43GBX. The last closing price is down -0.56% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.03% over the same time period. 874,867 shares of VEC traded hands, down from an average trading volume of 1,829,460

In a report released on 11/29/2016 finnCap hold steady the stock price target of Vectura Group PLC (LON:VEC) from 225.00GBX to 225.00GBX reporting a possible upside of 0.54%.

Previously on 11/24/2016, JP Morgan Cazenove reported on Vectura Group PLC (LON:VEC) held steady the target price at 230.00GBX. At the time, this indicated a possible upside of 0.53%.

Recent Performance Chart

Vectura Group PLC (LON:VEC)

Vectura Group PLC has 52 week low of 122.90GBX and a 52 week high of 200.10GBX and has a market capitalization of 0 GBX.

In addition to finnCap reporting its stock price target, a total of 6 brokers have issued a research note on the company. The average stock price target is 215.67GBX with 4 brokers rating the stock a strong buy, 2 brokers rating the stock a buy, 1 broker rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell.

Brief Synopsis On Vectura Group PLC (LON:VEC)

Vectura Group plc is engaged in research, development and commercialization of therapeutic products and drug delivery systems for human use. The Company's products include Ultibro Breezhaler (European Union (EU) and Rest of World (RoW)) – LABA-LAMA; Seebri Breezhaler (EU and RoW) – LAMA; AirFluSal Forspiro (EU and RoW) – ICS-LABA; ADVATE (Global) – Antihaemophilic Factor (Recombinant); Adept (Global) – Icodextrin; Anoro Ellipta (Global) – LAMA-LABA; Relvar Ellipta/Breo Ellipta (Global) – ICS-LABA, and Incruse Ellipta (Global) – LAMA. Its product pipeline includes VR588, VR475, VR647, VR942, VR179, VR736, VR096, VR876, VR315, VR506, VR632, Seebri Neohaler and VR465. Its dry powder inhalers (DPI) include GyroHaler, Lever-operated, Open-inhale-close and Unit Dose DPI. Its smart nebuliser delivery systems provide targeted inhalation therapy for applications where precise and targeted delivery of a drug to the lungs is needed. Its smart nebulizer delivery systems include AKITA JET and FOX.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *